# Follicular lymphoma

Source: https://nuclide.cc/indications/follicular-lymphoma/  
Nuclide record `follicular-lymphoma` (Indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year.

## Summary

Follicular lymphoma (FL) is an indolent germinal-centre B-cell lymphoma defined by t(14;18) BCL2 overexpression in ~85% and frequent CREBBP, KMT2D and EZH2 mutations. Median survival now exceeds 15-20 years, so the questions are when to treat, how to avoid over-treatment, and how to manage the ~20% who progress within 24 months (POD24) and the 2-3% per year who transform to DLBCL.

Asymptomatic low-burden disease is watched or given rituximab monotherapy; symptomatic or high-burden disease receives anti-CD20 (rituximab or obinutuzumab) with bendamustine, CHOP or CVP, or with lenalidomide (R², RELEVANCE), usually followed by anti-CD20 maintenance (PRIMA). Relapsed disease has the richest menu in lymphoma: lenalidomide-rituximab (AUGMENT), CD20×CD3 bispecifics (mosunetuzumab 2022, epcoritamab 2024, odronextamab EU), CD19 CAR-T (axicabtagene 2021, tisagenlecleucel 2022, lisocabtagene 2024), zanubrutinib-obinutuzumab (ROSEWOOD, 2024) and radioimmunotherapy historically. Tazemetostat (EZH2) was withdrawn worldwide in March 2026.

Open questions: whether bispecifics or CAR-T should move to second line or even first line (EPCORE FL-1, MorningSun), PET/ctDNA-guided de-escalation, and biology-based prediction of POD24 and transformation.

## Fields

- Kind: Indication
- Last checked: 2026-09-08
- Tags: gap-fill; haematologic
- Group: haematologic
- Burden: Follicular lymphoma is the second most common non-Hodgkin lymphoma in the West (~20% of NHL; about 3-4 per 100,000 per year), median age ~65.
- Subtypes: Classic FL (grades 1-3A); Follicular large B-cell lymphoma (formerly 3B); FL with unusual cytological features; Duodenal-type FL; Paediatric-type FL; Transformed FL
- Biomarkers: t(14;18)/BCL2; FLIPI / FLIPI2 / m7-FLIPI; PET-CT (Lugano) staging and end-of-induction response; POD24 (progression within 24 months); EZH2 mutation; ctDNA (investigational MRD)

## Standard of care

- Limited stage (I-II): Involved-site radiotherapy 24 Gy (FoRT); rituximab alone or observation in selected cases. ([Rituximab](https://nuclide.cc/drugs/rituximab/))
- Advanced, low burden, asymptomatic: Watch and wait (no survival penalty), or rituximab monotherapy to delay chemotherapy. ([Rituximab](https://nuclide.cc/drugs/rituximab/))
- Advanced, high burden (GELF criteria): Bendamustine-rituximab or bendamustine-obinutuzumab (GALLIUM), R-CHOP, or lenalidomide-rituximab (RELEVANCE); anti-CD20 maintenance 2 years (PRIMA). ([Rituximab](https://nuclide.cc/drugs/rituximab/))
- Relapsed (≥2 lines): Lenalidomide-rituximab (AUGMENT); CD20×CD3 bispecific (mosunetuzumab, epcoritamab); CD19 CAR-T (axi-cel, tisa-cel, liso-cel); zanubrutinib + obinutuzumab; clinical trials.

## State of the art

- Chemotherapy-free options now exist at every line: R² first line, bispecifics and BTK-anti-CD20 combinations at relapse.
- CAR-T gives durable remissions in heavily pretreated FL (ZUMA-5 ~50% progression-free at 4 years) and is being tested against bispecifics.
- POD24 identifies the high-risk fifth; how to treat them differently up front is still unknown.
- Trials of bispecific plus lenalidomide first line (EPCORE FL-2, CELESTIMO) will decide whether chemotherapy leaves front-line FL.

## Open problems

- Transformation to DLBCL cannot be predicted or prevented.
- Sequencing bispecifics vs CAR-T.
- Whether earlier intensive therapy for POD24 patients improves survival.
- Late toxicities of decades of therapy (secondary cancers, infections, immunoglobulin loss).

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Follicular_lymphoma
- NCCN Guidelines: B-Cell Lymphomas: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480
- NCI PDQ: adult NHL: https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq
- Lymphoma Research Foundation: FL: https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/fl/

## Connected records

- indications: [Diffuse large B-cell lymphoma](https://nuclide.cc/indications/dlbcl/)
- technologies: [PET/CT](https://nuclide.cc/technologies/pet-ct/), [Radio-antibody & radio-ADC](https://nuclide.cc/technologies/radioimmunotherapy/)
- targets: [CD20](https://nuclide.cc/targets/cd20/)
- drugs: [Ibritumomab tiuxetan](https://nuclide.cc/drugs/ibritumomab-tiuxetan/), [Iodine-131 tositumomab](https://nuclide.cc/drugs/i-131-tositumomab/), [Rituximab](https://nuclide.cc/drugs/rituximab/)
- companies: [Acrotech Biopharma](https://nuclide.cc/companies/acrotech-biopharma/)
- pairings: [Rituximab pretreatment before ibritumomab tiuxetan (Zevalin)](https://nuclide.cc/pairings/rituximab-then-ibritumomab-tiuxetan/)

---
JSON: https://nuclide.cc/api/v1/entities/follicular-lymphoma.json